Advertisement

Complications of Anticancer Drugs and Their Management

  • Kyu-Won Kim
  • Jae Kyung Roh
  • Hee-Jun Wee
  • Chan Kim
Chapter

Abstract

Anticancer therapy targets actively growing and dividing cells. Because of this characteristic, anticancer drugs assaults not only cancer cells but also normally proliferating cells such as blood cells, mucosal epithelial cells, and skin epithelial cells. Therefore, they inevitably have various side effects. Most of such side effects are mild and transient, but some can become severe and irreversible. To increase compliance with anticancer therapy and to maintain the quality of life of cancer patients, the complications of anticancer therapy must be well understood and properly managed.

Keywords

Anticancer Drug Tumor Lysis Syndrome Neutropenic Fever Hemorrhagic Cystitis Extravasation Site 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494CrossRefPubMedGoogle Scholar
  2. 2.
    Daniel D, Crawford J (2006) Myelotoxicity from chemotherapy. Semin Oncol 33:74–85, ElsevierCrossRefPubMedGoogle Scholar
  3. 3.
    Aapro M, Bohlius J, Cameron D et al (2012) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32CrossRefGoogle Scholar
  4. 4.
    Gibson RJ, Keefe DM (2006) Cancer chemotherapy-induced diarrhea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 14:890–900CrossRefPubMedGoogle Scholar
  5. 5.
    Hartmann JT, Lipp HP (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4:889–901CrossRefPubMedGoogle Scholar
  6. 6.
    Meisenberg B, Lassiter M, Hussein A et al (1994) Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. Bone Marrow Transplant 14:287–291PubMedGoogle Scholar
  7. 7.
    Luce JK, Simons JA (1988) Efficacy of mesna in preventing further cyclophosphamide-lnduced hemorrhagic cystitis. Med Pediatr Oncol 16:372–374CrossRefPubMedGoogle Scholar
  8. 8.
    Catane R, Schwade JG, Turrisi AT III et al (1979) Pulmonary toxicity after radiation and bleomycin: a review. Int J Radiat Oncol Biol Phys 5:1513–1518CrossRefPubMedGoogle Scholar
  9. 9.
    Park S, Krishnan A, Lin C et al (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081–3094CrossRefPubMedGoogle Scholar
  10. 10.
    Argyriou AA, Bruna J, Marmiroli P et al (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51–77CrossRefPubMedGoogle Scholar
  11. 11.
    Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633–1642CrossRefPubMedGoogle Scholar
  12. 12.
    Bovelli D, Plataniotis G, Roila F (2010) Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 21:277–282CrossRefGoogle Scholar
  13. 13.
    Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47–58CrossRefPubMedGoogle Scholar
  14. 14.
    Keefe DM, Schubert MM, Elting LS et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109:820–831CrossRefPubMedGoogle Scholar
  15. 15.
    Bruera E, Macmillan K, Kuehn N et al (1990) A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66:1279–1282CrossRefPubMedGoogle Scholar
  16. 16.
    Coiffier B, Altman A, Pui CH et al (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26:2767–2778CrossRefPubMedGoogle Scholar
  17. 17.
    Cortes J, Moore JO, Maziarz RT et al (2010) Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. J Clin Oncol 28:4207–4213CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Fidalgo JP, Fabregat LG, Cervantes A et al (2012) Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 23:167–173CrossRefGoogle Scholar
  19. 19.
    Huang V, Anadkat M (2011) Dermatologic manifestations of cytotoxic therapy. Dermatol Ther 24:401–410CrossRefPubMedGoogle Scholar
  20. 20.
    Janusch M, Fischer M, Marsch W et al (2006) The hand-foot syndrome-a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 16:494–499, 382PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Kyu-Won Kim
    • 1
  • Jae Kyung Roh
    • 2
  • Hee-Jun Wee
    • 1
  • Chan Kim
    • 3
  1. 1.College of PharmacySeoul National UniversitySeoulKorea (Republic of)
  2. 2.Department of Internal MedicineYonsei University College of MedicineSeoulKorea (Republic of)
  3. 3.Department of Internal MedicineCHA Bundang Medical CenterSeongnamKorea (Republic of)

Personalised recommendations